TSW
RCKT icon

Thompson Siegel & Walmsley’s Rocket Pharmaceuticals RCKT Stock Holding History

Thompson Siegel & Walmsley’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-46,747
Closed -$312K – 416
2025
Q1 		$312K Buy
46,747
+34,000
+267% +$336K 0.01% 355
2024
Q4 		$160K Buy
+12,747
New +$192K ﹤0.01% 376

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

Thompson Siegel & Walmsley's RCKT Position: Q2 2025 in Review

Thompson Siegel & Walmsley sold out of Rocket Pharmaceuticals (RCKT) in Q2 2025, closing a stake of 46,747 shares — an estimated $312K sold.

Thompson Siegel & Walmsley first reported a position in RCKT in Q4 2024 and held it in 2 quarters. The position peaked at $312K in Q1 2025. 196 funds tracked by Wall St. Rank hold RCKT as of Q2 2025.

  • Thompson Siegel & Walmsley reported no remaining Rocket Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Thompson Siegel & Walmsley sold 46,747 Rocket Pharmaceuticals shares in Q2 2025, an estimated $312K.
  • Thompson Siegel & Walmsley first reported a position in Rocket Pharmaceuticals in Q4 2024 and held it in 2 quarters.
  • Thompson Siegel & Walmsley's Rocket Pharmaceuticals position peaked at $312K in Q1 2025.
  • 196 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2025.

Based on Thompson Siegel & Walmsley's 13F filing for Q2 2025, filed 6 Aug 2025.